Pub. Date : 2002 Apr
PMID : 11901091
4 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | To this end, the kinetic profiles of three model CYP2C9 substrates (flurbiprofen, naproxen, and piroxicam) were studied using purified CYP2C9*1 (wild-type) and variants involving active site amino acid changes, including the naturally occurring variants CYP2C9*3 (Leu359) and CYP2C9*5 (Glu360) and the man-made mutant CYP2C9 F114L. | Flurbiprofen | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 2 | CYP2C9*1 (wild-type) metabolized each of the three compounds with a distinctive profile reflective of typical hyperbolic (flurbiprofen), biphasic (naproxen), and substrate inhibition (piroxicam) kinetics. | Flurbiprofen | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 3 | CYP2C9*3 metabolism was again hyperbolic for flurbiprofen, of a linear form for naproxen (no saturation noted), and exhibited substrate inhibition with piroxicam. | Flurbiprofen | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 4 | CYP2C9*5-mediated metabolism was hyperbolic for flurbiprofen and piroxicam but linear with respect to naproxen turnover. | Flurbiprofen | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |